Filter Results:
(128)
Show Results For
- All HBS Web
(380)
- People (2)
- News (141)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Show Results For
- All HBS Web
(380)
- People (2)
- News (141)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (72)
Sort by
- 02 Apr 2001
- Research & Ideas
Not All M&As Are Alike—and That Matters
Scenario 4: The M&a As R&d The next-to-last category, acquisitions as a substitute for in-house R&D, is related to product and market extensions, but I'll treat it separately because it's so new and untested. An assortment of high-tech and View Details
Keywords: by Joseph L. Bower
- 11 Apr 2011
- Lessons from the Classroom
Teaching a ‘Lean Startup’ Strategy
in the clean tech and biotech fields, both of which often require a great deal of time and capital to create any workable product. The same is true of the transportation industry—inventor Dean Kamen's Segway, for example, or startup... View Details
- 30 Jun 2021
- In Practice
The Harvard Business School Faculty Summer Reader 2021
many products and offer countless tips on how to lower your carbon footprint every day. Julia Austin (@austinfish) is an executive fellow at the Rock Center for Entrepreneurship and a former senior lecturer. Jeffrey Bussgang: Civil rights and View Details
Keywords: by Kathryn Haviland
- 15 Jun 2007
- Research & Ideas
Remembering Alfred Chandler
School, Al was just publishing Scale and Scope. I watched him move from this book, which dealt principally with Second Industrial Revolution industries, to a keen interest in telecommunications and the Information Revolution. Before long, Al was digging into View Details
Keywords: by Sean Silverthorne
- 15 Feb 2000
- Research & Ideas
The Right Connections
capital on their ability to secure resources. "In biotech it can take eight to ten years to develop a product and cost hundreds of millions of dollars to bring it to market," says Higgins. "Therefore, funding is... View Details
Keywords: by Judith A. Ross
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
research projects. A: There is a whole bunch of work being done on biotech, the biotech industry, and the future of pharmaceuticals. My stuff looks at a broader question: Can science be a business? This is the history of biotech, which is... View Details
- 07 Feb 2005
- Research & Ideas
How “Career Imprinting” Shapes Leaders
top biotech managers, companies leave an imprint of their worldview on young executives through such things as the firm's structure, strategy, and culture. There is a GE imprint, an IBM imprint, a Bain imprint—all of which influence... View Details
Keywords: by Mallory Stark
- 09 Aug 2010
- Research & Ideas
How to Speed Up Energy Innovation
Is there a special sauce for stimulating innovation in the energy sector, a concoction to spur cost-effective developments toward solving the climate change problem? HBS professor Rebecca Henderson doesn't claim to know all the ingredients for that special sauce. But... View Details
- 18 Oct 2010
- Lessons from the Classroom
Venture Capital’s Disconnect with Clean Tech
MBA students often fall into one of two categories—those hungry to rush into careers as venture capitalists, and those eager to found a venture-funded start-up. For all of them, Harvard Business School professor Joseph Lassiter has some intriguing advice: Spend a few... View Details
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Jeffrey Wiesen, an attorney specializing in biotechnology, the standard routine was "more a work-for-hire model than a collaboration model, although we always called it collaboration." In a nutshell, it worked like this, Wiesen said. "A View Details
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
its traditional slow-paced and bureaucratic system of R&D to emulate the relatively fast pace and entrepreneurial system of biotech companies." The firm created several specialized research teams to manage the innovation process.... View Details
Keywords: by Carmen Nobel
- 19 Sep 2012
- Research & Ideas
Book Excerpt: “The Architecture of Innovation”
but the fund achieved impressive successes. For instance, it invested in biotech firms like Amgen, Cephalon, and Sepracor, and coinvested with major venture firms such as Kleiner Perkins and New Enterprise Associates. Its compensation... View Details
- 12 Oct 2006
- First Look
First Look: October 12, 2006
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707438 PublicationsScience Business: Promise, Performance and the Future of Biotech Author:Gary P. Pisano Publication:Harvard Business School Press (forthcoming) Abstract... View Details
Keywords: Sean Silverthorne
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
move to one of the big tech clusters like San Francisco,” Kerr says. “Likewise, if you are a biotech entrepreneur, there are enormous advantages to being in the Boston area. But there are also a lot of inventors who work in spaces that... View Details
Keywords: by Rachel Layne
- 06 May 2008
- First Look
First Look: May 6, 2008
Fibrosis Foundation: Venture Philanthropy Funding for Biotech Harvard Business School Case 808-005 In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora... View Details
Keywords: Martha Lagace
- 26 Nov 2001
- Research & Ideas
Women Entrepreneurs Use Springboard for Funding
personalize healthcare and benefits, and Carol Nacy of Sequella, Inc., a biotech firm focused on controlling global infectious diseases, especially tuberculosis. Most of the companies were already up and running. Their funding to date has... View Details
Keywords: by Martha Lagace
- 01 Mar 2018
- What Do You Think?
Two Decades Later, is the 'New Economy' Finally Here?
second of these books, Exponential Organizations (“ExOs”), explores the impact of new technologies on organizations. These are organizations driven by such things as AI, robotics, biotech and bioinformatics, data science, and 3D printing.... View Details
Keywords: by James Heskett
- 24 May 2011
- First Look
First Look: May 24
case:http://cb.hbsp.harvard.edu/cb/product/211086-PDF-ENG Innovation and Growth at Actelion Ltd Gary P. Pisano, Daniela Beyersdorfer, and Ruth DittrichHarvard Business School Case 611-065 : In late 2010, Jean-Paul Clozel, CEO of the Swiss View Details
Keywords: Sean Silverthorne
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
science-based research is something the heads of top biotech and pharmas learned long ago: There are few instant payoffs to please investors. Just ask Raymond Gilmartin, former chairman, president, and CEO of Merck & Co., who now... View Details
- 17 Dec 2001
- Research & Ideas
Enterprising Women
by the firm's mission and saw that it had been self-sufficient for nearly seven years, Fisher's task became much easier: In three stages, over the course of 2000, she raised venture capital funds of $11 million, $48 million, and $75 million. That same year, she founded... View Details
Keywords: by Julia Hanna